Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

676 articles

Showing 1–1 of 1 articles · Keyword: Hepatitis B Clear keyword

Advanced pharmaceutical bulletin2026ReviewNon-viral Gene DeliveryDrug Delivery

1. Chemical Design and Therapeutic Efficacy of HBsAg-Based Nanovaccines for Hepatitis B Virus Clearance: A Preclinical and Clinical Systematic Review

Nequi Marnani H, Zadeh Mehrizi T, Eshrati B, Shafiee Ardestani M, Ajdary N, Vodjgani M, Et Al.

More than 240 million people worldwide are chronically infected with hepatitis B. Although current antiviral therapies effectively inhibit viral replication, they rarely result in a functional cure. The development of hepatitis B surface antigen (HBsAg)-based nanovaccines has emerged as a potential therapeutic…

Read the article
Articles | Brilliant Blue Biosciences